A single arm phase 1b study of everolimus and sunitinib in patients with advanced renal cell carcinoma (RCC)

BACKGROUND: Everolimus ,an oral inhibitor of mammalian target of rapamycin (mTOR), and sunitinib, an oral inhibitor of VEGF/PDGF receptor tyrosine kinase signaling, have both been shown to provide clinical benefit in patients with advanced RCC. We sought to determine the safety and efficacy of combi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Genitourin Cancer
Hlavní autoři: Kanesvaran, R., Watt, K., Turnbull, J. D., Armstrong, A. J., Cohen-Wolkowiez, M., George, D. J.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2014
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4754968/
https://ncbi.nlm.nih.gov/pubmed/26174223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2014.12.011
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky